These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube. Messaouik D; Sautou-Miranda V; Bagel-Boithias S; Chopineau J Int J Pharm; 2005 Aug; 299(1-2):65-72. PubMed ID: 15990258 [TBL] [Abstract][Full Text] [Related]
54. Quantification of omeprazole degradation by enteric coating polymers: an UV-VIS spectroscopy study. Riedel A; Leopold CS Pharmazie; 2005 Feb; 60(2):126-30. PubMed ID: 15739901 [TBL] [Abstract][Full Text] [Related]
55. [Effect of proton pump inhibitors. In vivo is decisive]. MMW Fortschr Med; 2002 Mar; 144(13):51. PubMed ID: 12001593 [No Abstract] [Full Text] [Related]
56. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Hoffman A; Stepensky D; Lavy E; Eyal S; Klausner E; Friedman M Int J Pharm; 2004 Jun; 277(1-2):141-53. PubMed ID: 15158977 [TBL] [Abstract][Full Text] [Related]
57. [Focus on proton pump inhibitors. The phenomenon of (over)compensation is not odd but normal]. Melander A Lakartidningen; 2003 Mar; 100(11):923. PubMed ID: 15148718 [No Abstract] [Full Text] [Related]
60. Factors Contributing to Drug Release From Enteric-Coated Omeprazole Capsules: An In Vitro and In Vivo Pharmacokinetic Study and IVIVC Evaluation in Beagle Dogs. Cui C; Sun J; Wang X; Yu Z; Shi Y Dose Response; 2020; 18(1):1559325820908980. PubMed ID: 32180688 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]